Effects of medium-term antihypertensive therapy on haemostatic parameters in patients with essential hypertension

Pathophysiology of Haemostasis and Thrombosis

Volumn 27, Issue 1, 1997, Pages 35-38

  Trifiletti, A ^a   Barbera, N ^a   Scamardi, R ^a   Bagnato, L ^a   Pizzoleo, M A ^a   Nevoso, A ^a   Lasco, A ^a   Pedulla M ^a   Frisina, N ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Angiotensin converting enzyme (ACE) inhibitor; Arterial hypertension; Haemostatic system

Indexed keywords

ANTIHYPERTENSIVE AGENT; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD COAGULATION; BLOOD PRESSURE; CILAZAPRIL; FEMALE; HEMOSTASIS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 0030933950     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217431     Document Type: Article

References (18)

1. Bardin AI: Study of atherogenic, coagulant and cardio-cerebral risk factors in the pathogenesis of minor strokes in arterial hypertension. Zh Nevropatol Psikhiatr 1991;91:46-50.
2. Trifilctti A, Barbera N, Pizzoleo MA, Lasco A. Lucifora S, Leone G. Soraci S. Pedulla M. Frisina N: Haemostatic variables in arterial hypertension. Haemostasis 1995:25:237-240.
3. Vaziri ND. Smith DH. Winer RL, Weber MA, Gonzales EC. Neutel JM: Coagulation of inhibitory and fibrinolysis proteins in essential hypertension. J Am Soc Nephrol 1993; 4:222-228.
4. van Wcrsch JW, Rompelberg-La-haye J. Lustermans FA: Plasma concentration of coagulation and fibrinolysis factors and platelet function in hypertension. Eur J Clin Chem Clin Biochem 1991;29:375-379.
5. Ixmne C, Vesterqvist O. Egbcrg N, Green K, Jogestrand T. de Faire U: Platelet activation and prostacyclin release in essential hypertension. Prostaglandins 1992;44:219-235.
6. Urano T. Kojima Y, Takahashi M. Scrizawa K, Takada Y, Takada A: Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator-inhibitor-1 level in plasma. Jpn J Physiol 1993,43: 221-228.
7. Donders SH, Lustermans FA. van Wersh JW: Low order correlations of lipoprotcin(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients. Blood Coagul Fibrinolysis 1992;3:249-256.
8. Donders SH, Lustermans FA, van Wersch JW: Fibrinolysis factors and lipid composition of the blood in treated and untreated hypertensive patients. Blood Coagul Fibrinolysis 1992;3:61-67.
9. Sushko OO, Lezhen TI, Platonova TM. Chernishcnko TM: A rapid tur-bidimetric micromethod in the determination of haemostatic and fibrinolytic disorders in arterial hypertensive patients of different ages. Vrach Delo 1993;7:58-60.
10. Amstein R, Fetkovska N, Bhuler FR: Age, platelet kinetics and 5HT2-receptor blockade in essential hypertension. J Hum Hypertens 1990;4:441-444.
11. Gomi T, Ikeda T. Yuhara M, Saku-rai J, Nakajama D, Ikegami F: Plasma beta-thromboglobulin to platelet factor 4 ratios as indices of vascular complications in essential hypertension. J Hypertens 1988;6:389-392.
12. Winther K, Glccrup G, Hedner T: Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: Has antihypertensive therapy any influence? J Cardiosvasc Pharmacol 1992;19 (suppl 3):21-24.
13. Winther K, Gleerup G, Hedner T: Platelet function and fibrinolytic activity in hypertension: Differential effects of calcium antagonists and beta-adrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18 (suppl 9):41-44.
14. Gleerup G, Hedner T, Hiorting Hansen E. Winther K: Docs antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991; 18 (suppl 3):34-36.
15. Wichmann C. Zahringer J: Modification of blood coagulation by anti-hypertensive therapy? Effect of enal-april and hydrochlorothiazide on blood coagulation parameters in patients with essential hypertension. FortschrMed 1989;107:521-524.
16. Winther K, Knudsen JB, Gormsen J, Jensen J: Effect of metoprolol and propranolol on platelet and cAMP level in hypertensive patients. Eur J Clin Pharmacol 1986;29:561-564.
17. Jansson JH, Johansson B, Boman K, Nilsson TK: Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated scrum cholesterol. Eur J Clin Pharmacol 1991;40:321-326.
18. Winther K: The effect of bcta-block-ade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 1987; 10(suppl 2):94-98.